Literature DB >> 19390669

The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy.

Scott A Macdiarmid1.   

Abstract

Multiple antimuscarinic agents are available for the treatment of overactive bladder. Many of the agents have undergone reformulation in an attempt to improve patient adherence and drug tolerability. Oxybutynin evolved from an immediate-release pill to a once-daily oral preparation, and is now available as a transdermal patch and gel. This article discusses the clinical impact of oxybutynin reformulation and reviews the evolution and benefits of transdermal therapy.

Entities:  

Keywords:  Oxybutynin; Reformulation; Transdermal therapy

Year:  2009        PMID： 19390669      PMCID： PMC2668835     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  25 in total

Review 1.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

Review 2.  Transdermal delivery of drugs for urologic applications: basic principles and applications.

Authors:  Victor W Nitti; Steven Sanders; David R Staskin; Roger R Dmochowski; Peter K Sand; Scott MacDiarmid; Howard I Maibach
Journal:  Urology       Date:  2006-04       Impact factor: 2.649

Review 3.  Medical treatment and medical side effects in urinary incontinence in the elderly.

Authors:  J W Thüroff; E Chartier-Kastler; J Corcus; J Humke; U Jonas; H Palmtag; E A Tanagho
Journal:  World J Urol       Date:  1998       Impact factor: 4.226

4.  Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland.

Authors:  K Waldeck; B Larsson; K E Andersson
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

Review 5.  Transdermal drug delivery and cutaneous metabolism.

Authors:  R H Guy; J Hadgraft; D A Bucks
Journal:  Xenobiotica       Date:  1987-03       Impact factor: 1.908

Review 6.  Compliance with treatment regimens in chronic asymptomatic diseases.

Authors:  N H Miller
Journal:  Am J Med       Date:  1997-02-17       Impact factor: 4.965

7.  Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.

Authors:  Tomomi Oki; Ayako Toma-Okura; Shizuo Yamada
Journal:  J Pharmacol Exp Ther       Date:  2005-11-10       Impact factor: 4.030

8.  Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group.

Authors:  D M Gleason; J Susset; C White; D R Munoz; P K Sand
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

Review 9.  Interventions for helping patients to follow prescriptions for medications.

Authors:  R B Haynes; H McDonald; A X Garg; P Montague
Journal:  Cochrane Database Syst Rev       Date:  2002

10.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226
View more
  7 in total

1.  Defining efficacy in the treatment of overactive bladder syndrome.

Authors:  Sagar Shah; Victor W Nitti
Journal:  Rev Urol       Date:  2009

2.  Topical use of Matricaria recutita L (Chamomile) Oil in the Treatment of Monosymptomatic Enuresis in Children: A Double-Blind Randomized Controlled Trial.

Authors:  Hosein Sharifi; Mohammad Bagher Minaie; Mohammad Javad Qasemzadeh; Nematollah Ataei; Mohammad Gharehbeglou; Mojtaba Heydari
Journal:  J Evid Based Complementary Altern Med       Date:  2015-09-30

Review 3.  Management of overactive bladder.

Authors:  Dev M Gulur; Marcus J Drake
Journal:  Nat Rev Urol       Date:  2010-10       Impact factor: 14.432

Review 4.  An update on the use of transdermal oxybutynin in the management of overactive bladder disorder.

Authors:  Joshua A Cohn; Elizabeth T Brown; W Stuart Reynolds; Melissa R Kaufman; Douglas F Milam; Roger R Dmochowski
Journal:  Ther Adv Urol       Date:  2016-01-19

5.  Will the evolution of overactive bladder delivery systems increase patient compliance?

Authors:  Nirit Rosenblum
Journal:  Rev Urol       Date:  2009

6.  Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?

Authors:  Raúl Vozmediano-Chicharro; Blanca Madurga; Pedro Blasco
Journal:  Adv Urol       Date:  2018-07-29

Review 7.  Update on the management of overactive bladder: patient considerations and adherence.

Authors:  Alex Gomelsky; Roger R Dmochowski
Journal:  Open Access J Urol       Date:  2010-12-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.